

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



\Rightarrow Spotlight on Special Topics

CARDIOVASCULAR DISEASE AND OUTCOMES IN CRITICALLY ILL PATIENTS WITH COVID-19: A STOP-COVID ANCILLARY

Poster Contributions Sunday, May 16, 2021, 12:15 p.m.-1:00 p.m.

Session Title: Spotlight on Special Topics: COVID 5 Abstract Category: 61. Spotlight on Special Topics: Coronavirus Disease (COVID-19)

Authors: <u>Chelsea Meloche</u>, Tariq U. Azam, Elizabeth Anderson, Husam Shadid, Hanna Berlin, Michael Pan, Rafey Feroze, Patrick O'Hayer, Abbas Bitar, Kishan Padalia, Erinleigh Michaud, Christopher Launius, Penelope Blakely, Shruti Gupta, David E. Leaf, Salim Hayek, University of Michigan, Ann Arbor, MI, USA

Background: Patients with pre-existing cardiovascular disease (CVD) and coronavirus disease (COVID-19) are perceived to be at higher risk of poor in-hospital outcomes. Multicenter data on the impact of CVD on COVID-19 related outcomes are lacking. We leveraged the multicenter Study of the Treatment and Outcomes in Critically III Patients with COVID-19 (STOP-COVID) to determine the prevalence of pre-existing CVD in critically ill patients with COVID-19 and assess its impact on in-hospital outcomes.

Methods: STOP-COVID is a multicenter prospective study that included adults (≥18 years) admitted to critical care units at 68 hospitals from 3/2020 to 6/2020 (n=5019). We identified patients with pre-existing coronary artery disease (CAD), heart failure (HF) and atrial fibrillation or flutter (AF) and collected clinical data on risk factors and troponin levels. Myocardial injury was defined as a troponin level above the upper limit of normal. We used binary logistic regression to examine the association between pre-existent CVD, myocardial injury and in-hospital death.

Results: 1149 patients (22.9%) had a history of CVD, including 13.5% with CAD, 10.2% with HF and 7.6% with AF. Compared to patients without CVD, those with were older (mean 69 vs 59 years, P<0.001), had a higher burden of hypertension (84.9% vs 54.5%, P<0.001), diabetes mellitus (55.6% vs 38.0%, P<0.001) and higher incidence of myocardial injury on day 1 of admission (39.9% vs 20.8%, P<0.001). Patients with CVD had significantly higher in-hospital mortality compared to those without (51.9% vs 37.4%, P<0.001). However, after adjusting for age, gender and BMI, CVD was not associated with an increased risk of death (OR 1.16 95% CI [0.84-1.61], P=0.38). Myocardial injury was associated with in-hospital death (OR 1.57 95% CI [1.39-1.81], P<0.001) independently of clinical characteristics including pre-existing CVD. Incident AF occurred in 10.3% and new HF in 3.3% of patients without CVD.

Conclusion: Pre-existing CVD is not independently associated with in-hospital mortality in critically ill patients with COVID-19. Myocardial injury is however common and independently associated with death, likely reflecting the severity of COVID-19.